同步的乳腺和结肠直肠恶性瘤-一个系统性审查
Cristian Iorga1,2, Cristina Raluca Iorga1,2, Alexandru Grigorescu1,3
1Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Life (Basel, Switzerland)
|August 29, 2024
概括
同步的乳腺和结直肠瘤是罕见的,通常在初始癌症治疗期间诊断出来. 治疗需要个性化的瘤委员会决定,可能涉及组合或分阶段的手术.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 手术瘤学手术瘤学
背景情况:
- 同步乳腺和结直肠瘤很少出现,但存在独特的临床挑战.
- 诊断通常发生在初始原发性癌症的调查期间.
研究的目的:
- 划分与同步乳腺和结直肠恶性瘤相关的诊断和治疗复杂性.
主要方法:
- 从1970年到2023年,根据PRISMA 2020指南进行了系统的文献审查.
- 关键词包括"同步乳腺和结肠瘤"和同义词.
- 数据提取和质量评估由五位审查员独立进行.
主要成果:
- 分析了15例病例,主要是女性 (13/15),平均年龄为60岁.
- 结肠直肠癌在9例乳腺癌之前发生;乳腺癌在6例结肠直肠癌之前发生.
- 侵袭性导管癌和腺癌分别是最常见的组织病理类型. 在大多数情况下,对于这两种瘤都适用于手术干预,同时观察到并发或分阶段的手术.
结论:
- 多学科瘤委员会 (T.B.) 咨询对于同步乳腺癌和结直肠癌的个性化治疗策略至关重要.
- 对新型诊断和治疗方法的进一步研究对于改善对这些罕见的双重恶性瘤的理解和结果至关重要.
更多相关视频
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
5.6K
08:26Clinical Application of Single-Surgeon, Three-Port, Laparoscopic Resection for Colorectal Cancer with Natural Orifice Specimen Extraction
Published on: March 24, 2023
412
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K